Drug Profile
Latozinemab - Alector
Alternative Names: AL-001; GSK-4527223Latest Information Update: 12 Feb 2024
Price :
$50
*
At a glance
- Originator Adimab; Alector
- Developer Alector; GSK
- Class Antidementias; Immunotherapies; Monoclonal antibodies; Neuroprotectants; Recombinant proteins
- Mechanism of Action Sortilin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Amyotrophic lateral sclerosis; Frontotemporal dementia
Most Recent Events
- 07 Feb 2024 Latozinemab - Alector receives Breakthrough Therapy status for Frontotemporal dementia in USA
- 31 Dec 2023 Alector and GSK helds a Type C meeting with the USFDA regarding the pivotal INFRONT-3 phase III trial
- 31 Dec 2023 Alector and GSK receives scientific advice from the European Medicines Agency (EMA) regarding the pivotal INFRONT-3 phase III trial